Outcome Analysis of a Series of Mixed-Grade, Non-muscle Invasive, Papillary Carcinomas of the Bladder
International Journal of Surgical Pathology · 2025
DOI: 10.1177/10668969241246492 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Surgical Pathology, 2025. Verfasst von Meagan Chambers und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Papillary, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Papillary urothelial carcinomas are currently graded as either low- or high-grade tumors based on World Health Organization (WHO) 2022 guidelines for genitourinary tumors. However, a minority of tumors are mixed-grade tumors, composed predominantly of low-grade cancer with a minor high-grade component. In the 2022 WHO these cancers are recognized as having outcomes comparable to low-grade cancers, although data to date has been limited.
Methods
The pathology records of a large academic institution were searched for mixed-grade, non-muscle invasive papillary carcinomas of the bladder and ureter in order to characterize prognosis of these cancers.
Results
Of 136 cancers, the majority (n = 104, 76.5%) were solitary, mixed-grade tumors, while 21 (15.4%) had a concurrent low-grade cancer and 11 (8.1%) had multiple mixed-grade tumors at the time of diagnosis. At follow-up (median 48.3 months, range = 1.3 months-18.1 years), 71 cancers recurred (52.2%): 52 (38.2%) as low- or mixed-grade cancers and 18 (13.2%) as high-grade cancers. There were no instances of stage-progression to >p T2.
Conclusions
The clinical outcome of mixed-grade carcinomas was similar to what has been reported for low-grade carcinomas. Based on our results, and prior congruent studies of mixed-grade lesions, these lesions may be regarded as a distinct sub-category with a better prognosis than high-grade tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
- University of Washington Medical School, Seattle, WA, USA.
- Department of Urology, University of Washington, Seattle, WA, USA.
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- Department of Mechanical Engineering, University of Washington, Seattle, WA, USA.
ORCID-Profile: Meagan Chambers, Maria Tretiakova
Zitieren
APA
Chambers, M., Andre, A. T., Wright, J. L., Vakar-Lopez, F., Tretiakova, M., Reder, N. P., Haffner, M. C., & True, L. D. (2025). Outcome Analysis of a Series of Mixed-Grade, Non-muscle Invasive, Papillary Carcinomas of the Bladder. International Journal of Surgical Pathology. https://doi.org/10.1177/10668969241246492
Vancouver
Chambers M, Andre AT, Wright JL, Vakar-Lopez F, Tretiakova M, Reder NP, et al. Outcome Analysis of a Series of Mixed-Grade, Non-muscle Invasive, Papillary Carcinomas of the Bladder. International Journal of Surgical Pathology. 2025. doi:10.1177/10668969241246492
BibTeX
@article{Chambers2025,
author = {Chambers, Meagan and Andre, Alexa T and Wright, Jonathan L and Vakar-Lopez, Funda and Tretiakova, Maria and Reder, Nicholas P and Haffner, Michael C and True, Lawrence D},
title = {Outcome Analysis of a Series of Mixed-Grade, Non-muscle Invasive, Papillary Carcinomas of the Bladder},
journal = {International Journal of Surgical Pathology},
year = {2025},
doi = {10.1177/10668969241246492}
}
EUVIMED